ZEPOSIA, a treatment for multiple sclerosis is the first and only approved sphingosine-1-phosphate (S1P) receptor modulator with no genetic test or first dose observation at initiation
Research from, Oxford's Com-Cov study highlights how mixing vaccine brands during follow-up covid vaccinations increases the risk of mild to moderate side effects.